Cargando…

Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers

BACKGROUND: The BRCA1 gene plays a key role in triple negative breast cancers (TNBCs), in which its expression can be lost by multiple mechanisms: germinal mutation followed by deletion of the second allele; negative regulation by promoter methylation; or miRNA-mediated silencing. This study aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boukerroucha, Meriem, Josse, Claire, ElGuendi, Sonia, Boujemla, Bouchra, Frères, Pierre, Marée, Raphaël, Wenric, Stephane, Segers, Karin, Collignon, Joelle, Jerusalem, Guy, Bours, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618357/ https://www.ncbi.nlm.nih.gov/pubmed/26490435 http://dx.doi.org/10.1186/s12885-015-1740-9

Ejemplares similares

BRCA1 germline mutation and glioblastoma development: report of cases
por: Boukerroucha, Meriem, et al.
Publicado: (2015)

Transcriptome-wide analysis of natural antisense transcripts shows their potential role in breast cancer
por: Wenric, Stephane, et al.
Publicado: (2017)

Circulating microRNA-based screening tool for breast cancer
por: Frères, Pierre, et al.
Publicado: (2015)

Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients
por: Frères, Pierre, et al.
Publicado: (2018)

Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment
por: Onesti, Concetta Elisa, et al.
Publicado: (2018)

Triple-negative breast cancer: treatment challenges and solutions
por: Collignon, Joëlle, et al.
Publicado: (2016)

Case Report Series: Aggressive HR Deficient Colorectal Cancers Related to BRCA1 Pathogenic Germline Variants
por: Freire, Maria Valeria, et al.
Publicado: (2022)

Differences in plasma microRNA content impair microRNA-based signature for breast cancer diagnosis in cohorts recruited from heterogeneous environmental sites
por: Uyisenga, Jeanne P., et al.
Publicado: (2021)

Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy
por: Onesti, Concetta Elisa, et al.
Publicado: (2019)

Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes
por: Jerusalem, Guy, et al.
Publicado: (2014)

Natural Antisense Transcripts: Molecular Mechanisms and Implications in Breast Cancers
por: Latgé, Guillaume, et al.
Publicado: (2018)

Screening of germline mutations in young Rwandan patients with breast cancers
por: Uyisenga, Jeanne P., et al.
Publicado: (2020)

Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer
por: Bovy, Nicolas, et al.
Publicado: (2015)

Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse
por: Onesti, Concetta Elisa, et al.
Publicado: (2020)

Immunity and Breast Cancer: Focus on Eosinophils
por: Poncin, Aurélie, et al.
Publicado: (2021)

BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
por: Jacot, William, et al.
Publicado: (2020)

Using Supervised Learning Methods for Gene Selection in RNA-Seq Case-Control Studies
por: Wenric, Stephane, et al.
Publicado: (2018)

New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
por: Vergote, I, et al.
Publicado: (2016)

A next-generation newborn screening pilot study: NGS on dried blood spots detects causal mutations in patients with inherited metabolic diseases
por: Boemer, F., et al.
Publicado: (2017)

Exploiting genomic surveillance to map the spatio-temporal dispersal of SARS-CoV-2 spike mutations in Belgium across 2020
por: Bollen, Nena, et al.
Publicado: (2021)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

Oncological patients' reactions to COVID‐19 pandemic: A single institution prospective study
por: Onesti, Concetta Elisa, et al.
Publicado: (2021)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Kitahara, Miyuki, et al.
Publicado: (2021)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
por: Bouwman, Peter, et al.
Publicado: (2010)

The role of BRCA status on prognosis in patients with triple-negative breast cancer
por: Xie, Yuxin, et al.
Publicado: (2017)

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
por: Pogoda, Katarzyna, et al.
Publicado: (2020)

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib
por: Yip, Cassandre, et al.
Publicado: (2017)

Ageism and its clinical impact in oncogeriatry: state of knowledge and therapeutic leads
por: Schroyen, Sarah, et al.
Publicado: (2014)

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
por: MAKSIMENKO, JELENA, et al.
Publicado: (2014)

Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast Tumors
por: Darbeheshti, Farzaneh, et al.
Publicado: (2018)

Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer
por: Emborgo, Trisha S, et al.
Publicado: (2020)

Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

Risk of metastasis in BRCA2 carriers diagnosed with triple‐negative breast cancer
por: Moreno, Marcelo, et al.
Publicado: (2023)

1712P Risk of SARS-CoV-2 infection and outcome after infection: Experience from the day-care unit at CHU Liège in Belgium
por: Lecocq, M., et al.
Publicado: (2020)

Prevalence of BRCA1 and BRCA2 mutations in Japanese patients with triple-negative breast cancer: A single institute retrospective study
por: Fujisawa, Fumie, et al.
Publicado: (2021)

Maestros y claves de la postura
por: Freres, Michel

Cannot write session to /tmp/vufind_sessions/sess_vahlk34pphjpiieadmjhae67td